Effect of carbohydrate feeding on the bone metabolic response to running by Sale C et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 3.0 Unported License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Sale C, Varley I, Jones TW, James RM, Tang JCY, Fraser WD, Greeves JP.  
Effect of carbohydrate feeding on the bone metabolic response to running.  
Journal of Applied Physiology 2015, 119(7), 824-830. 
 
 
Copyright: 
Copyright © 2015 the American Physiological Society.  
Licensed under Creative Commons Attribution CC-BY 3.0 
DOI link to article: 
http://dx.doi.org/10.1152/japplphysiol.00241.2015 
Date deposited:   
31/03/2016 
 
Effect of carbohydrate feeding on the bone metabolic response to running
Craig Sale,1 Ian Varley,1 Thomas W. Jones,2 Ruth M. James,1 Jonathan C. Y. Tang,3 William D. Fraser,3,4
and Julie P. Greeves5
1Musculoskeletal Physiology Research Group, Sport, Health and Performance Enhancement Research Centre, School of
Science and Technology, Nottingham Trent University, Nottingham, United Kingdom; 2Institute of Neuroscience, Newcastle
University, Newcastle upon Tyne, United Kingdom; 3Norwich Medical School, University of East Anglia, Norwich, United
Kingdom; 4Norfolk and Norwich University Hospital, Norwich, United Kingdom; and 5Department of Occupational Medicine,
HQ Army Recruiting and Training Division, Upavon, United Kingdom
Submitted 19 March 2015; accepted in final form 30 July 2015
Sale C, Varley I, Jones TW, James RM, Tang JC, Fraser WD,
Greeves JP. Effect of carbohydrate feeding on the bone metabolic
response to running. J Appl Physiol 119: 824–830, 2015. First
published August 6, 2015; doi:10.1152/japplphysiol.00241.2015.—
Bone resorption is increased after running, with no change in bone
formation. Feeding during exercise might attenuate this increase,
preventing associated problems for bone. This study investigated the
immediate and short-term bone metabolic responses to carbohydrate
(CHO) feeding during treadmill running. Ten men completed two
7-day trials, once being fed CHO (8% glucose immediately before,
every 20 min during, and immediately after exercise at a rate of 0.7 g
CHO·kg body mass1·h1) and once being fed placebo (PBO). On
day 4 of each trial, participants completed a 120-min treadmill run at
70% of maximal oxygen consumption (V˙ O2 max). Blood was taken at
baseline (BASE), immediately after exercise (EE), after 60 (R1) and
120 (R2) min of recovery, and on three follow-up days (FU1-FU3).
Markers of bone resorption [COOH-terminal telopeptide region of
collagen type 1 (-CTX)] and formation [NH2-terminal propeptides
of procollagen type 1 (P1NP)] were measured, along with osteocalcin
(OC), parathyroid hormone (PTH), albumin-adjusted calcium (ACa),
phosphate, glucagon-like peptide-2 (GLP-2), interleukin-6 (IL-6),
insulin, cortisol, leptin, and osteoprotogerin (OPG). Area under the
curve was calculated in terms of the immediate (BASE, EE, R1, and
R2) and short-term (BASE, FU1, FU2, and FU3) responses to exer-
cise. -CTX, P1NP, and IL-6 responses to exercise were significantly
lower in the immediate postexercise period with CHO feeding com-
pared with PBO (-CTX: P  0.028; P1NP: P  0.021; IL-6: P 
0.036), although there was no difference in the short-term response
(-CTX: P  0.856; P1NP: P  0.721; IL-6: P  0.327). No other
variable was significantly affected by CHO feeding during exercise.
We conclude that CHO feeding during exercise attenuated the -CTX
and P1NP responses in the hours but not days following exercise,
indicating an acute effect of CHO feeding on bone turnover.
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FEEDING INFLUENCES the circadian rhythm of bone metabolism at
rest (21). Markers of bone resorption decrease after mixed-
meal feeding (3) and ingestion of individual macronutrients at
rest (1, 7). Reductions in bone resorption occur after oral but
not parenteral administration of glucose, suggesting that en-
teric hormones might play a part in mediating the effects of
glucose on bone metabolism (1). This is supported by studies
showing that administration of octreotide, an inhibitor of en-
teric hormone secretion, abolishes the reduction in bone re-
sorption following glucose ingestion (4). These findings sug-
gest a potential means to modulate bone turnover by nutritional
strategies or through manipulation of dietary composition (25).
Exhaustive weight-bearing exercise increases bone resorp-
tion by 40–45% for up to four consecutive days without a
concomitant increase in bone formation, potentially resulting
in a short-term net loss of bone (19). Attenuating bone resorp-
tion is a potential countermeasure to the bone uncoupling
shown to occur with exercise that might predispose athletes
and military recruits to stress fractures and other associated
injuries (26). Feeding practices, before, during, and after ex-
ercise, influence the interaction between exercise and bone
turnover, making them potentially important for offsetting
bone loss. Scott et al. (22) showed that feeding a mixed meal
prior to exercise reduced COOH-terminal telopeptide region of
collagen type 1 (-CTX) concentrations before a 60-min tread-
mill run, although the subsequent increase in -CTX during
exercise was similar in fed and fasted groups. This indicated a
novel interaction between feeding, exercise, and bone metab-
olism that requires further study, particularly in relation to
feeding practices during and after exercise.
Carbohydrate (CHO), fat, and protein all decrease -CTX
(3, 4); CHO ingestion during exercise is an established nutri-
tional practice for athletes, proven to enhance physical perfor-
mance and exercise capacity by providing additional fuel to the
muscle (11). A recent study (5) suggests that CHO is a
candidate nutrient for modulating bone resorption during an
exercise program (8-day intensive training), although factors
that may have mediated these responses were not examined.
The aim of this study was to investigate the responses of
bone metabolism to CHO feeding during exercise in the hours
(immediate) and days (short term) following a single bout of
strenuous treadmill running. We also measured markers asso-
ciated with feeding, exercise, and bone to explore possible
mediating and mechanistic factors.
METHODS
Participants
Ten healthy, physically active men [means  SD: age 24  3 yr,
height 1.75  0.08 m, body mass 72.9  7.5 kg, body fat percentage
14.3  2.4%, maximal oxygen consumption (V˙ O2 max) 53.0  6.4
ml·kg1·min1] provided informed consent and completed medical
history questionnaires. The institutional research ethics committee
approved the study in accordance with the Declaration of Helsinki.
Participants were included if they were nonsmokers, had not
suffered a bone fracture or injury of any type in the previous 12 mo,
were free from musculoskeletal injury, were not taking any medica-
tion, and were not suffering from any condition known to affect bone
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metabolism. Eligibility of each participant was confirmed verbally and
with a medical screening questionnaire.
Experimental Design
All participants completed two randomized, repeated-measures,
counterbalanced 7-day experimental trials, involving either placebo
(PBO) or CHO ingestion during 120 min of treadmill running at 70%
of V˙ O2 max. Trials were separated by 14 days to allow participants to
recover from blood sampling and dietary control and to allow bone
marker concentrations to return to baseline values. Participants were
required to refrain from exercise and caffeine and alcohol consump-
tion for 48 h prior to trials. Participants recorded dietary intake during
the first trial and repeated the same dietary pattern during the second
trial to control for the influence of feeding on bone metabolism (25).
Experimental Procedures
Preliminary measurements. Height and body mass were recorded
before body fat analysis was conducted by bioelectrical impedance
(Bodystat 1500, Bodystat, Douglas, Isle of Man, UK). Preliminary
testing also involved the assessment of the cardiorespiratory responses
to running. Participants first performed a submaximal test to establish
the relationship between running speed and oxygen consumption
during level running, which was completed at a 0% gradient from a
gentle starting speed. The speed of the treadmill was increased by 1
km/h at 3-min intervals for at least 15 min (5 stages). Expired air (1
min, inspiration to inspiration) was collected into Douglas bags during
the last minute of each stage to determine oxygen consumption.
Oxygen consumption at each stage of the submaximal test was plotted
against the running speed at that stage so that the relationship between
running speed and oxygen consumption could be determined.
The maximum oxygen uptake test was then performed after a
15-min recovery period, consisting of a continuous incremental uphill
running test at constant speed until volitional exhaustion. Running
speed for this test was determined from the results of the submaximal
test. The gradient of the treadmill was increased by 1% at the end of
each minute from a starting gradient of 0%. Once maximum oxygen
uptake was determined, the oxygen consumption representing 70%
V˙ O2 max was calculated. With the data from the submaximal running
test, the running speed that elicited 70% V˙ O2 max at a 0% gradient was
determined.
Trial days 1–3. Participants adhered to their normal diet and
refrained from exercise or strenuous physical exertion. Participants
recorded their dietary intake and were asked about lifestyle activity
(e.g., feelings of fatigue, sleep patterns), with diet and sleep patterns
being replicated between trials.
Trial day 4. Participants attended the laboratory (0800) after an
overnight fast (since 2000 the previous evening) and remained fasted
until the final blood sample was drawn. On arrival, nude body mass
was determined and participants then rested in a semirecumbent
position and were fitted with a heart rate monitor (Polar FS1, Polar
Electro). At 0830, a resting blood sample (BASE) was withdrawn
from a prominent forearm vein. Participants then completed 120 min
of running on a treadmill (h/p/cosmos, Pulsar 4.0) at 70% V˙ O2 max.
Further blood samples were withdrawn immediately after exercise
(EE) (1100) and after 60 (R1) (1200) and 120 (R2) (1300) min of
recovery. Heart rate (HR) and rating of perceived exertion (RPE;
6–20 scale) were recorded before exercise and at 10-min intervals
throughout exercise for participant monitoring purposes.
During the CHO trial, participants ingested an 8% glucose solution
immediately before, every 20 min during, and immediately after
exercise at a rate of 0.7 g CHO·kg body mass1·h1. The total amount
of glucose ingested was 102.1  10.6 g in a total solution volume of
1,276  132 ml. These totals were divided equally over seven mean
ingestions of 14.6  1.5 g of glucose in 182  19 ml of solution.
During the PBO trial, participants ingested equal volumes of a
taste-matched flavored water drink containing no CHO.
Upon completion of exercise, nude body mass was determined and
participants consumed water equal to 150% of the body mass lost over
the subsequent 120 min. Participants were instructed not to perform
any further exercise.
Trial days 5–7. Participants attended the laboratory (0800) after an
overnight fast (from 2000 the previous evening) and rested for 30 min,
after which a blood sample was withdrawn (0830) from a prominent
forearm vein. During this time, participants continued to record their
diet and maintained dietary control and refrained from all exercise.
Storage and Analyses of Venous Blood
Fifteen milliliters of venous blood was dispensed into three 5-ml
tubes lined with ethylenediaminetetraacetic acid (EDTA) and centri-
fuged immediately for 10 min at 2,000 g and 4°C. After centrifuga-
tion, plasma was dispensed into Eppendorf tubes and stored at80°C
for subsequent analyses of COOH-terminal telopeptide region of
collagen type 1 (-CTX), NH2-terminal propeptides of procollagen
type 1 (P1NP), osteoprotogerin (OPG), osteocalcin (OC), parathyroid
hormone (PTH), leptin, glucagon-like peptide-2 (GLP-2), and inter-
leukin-6 (IL-6). Prior to storage, measurements of plasma glucose and
lactate were performed (Yellow Springs Instruments 2300 STAT Plus,
YSI).
-CTX, P1NP, OC, and PTH were measured by electrochemilu-
minescent immunoassay (ECLIA) on a Modular Analytics E170
analyzer (Roche Diagnostics, Burgess Hill, UK). Interassay coeffi-
cient of variation (CV) for -CTX was 3% between 0.2 and 1.5
g/l, with sensitivity of 0.01 g/l. P1NP interassay CV was 3%
between 20 and 600 g/l, with sensitivity of 8 g/l. OC interassay CV
was 5% between 2 and 200 g/l, with sensitivity of 0.6 g/l. PTH
interassay CV was 4% between 1 and 30 pmol/l, with sensitivity of
0.8 pmol/l. OPG was measured with an enzyme-linked immunosor-
bent assay (ELISA) supplied by Immuno Diagnostic Systems (IDS,
Boldon, UK), with an interassay CV of 8% across the range 1–30
pmol/l and sensitivity of 0.14 pmol/l. Leptin was measured by ELISA
supplied by IDS, having an interassay CV of 8% across the range
3–50 g/l and sensitivity of 1 g/l. GLP-2 was measured by ELISA
(Yanaihara Institute), with an interassay CV of 1.1–11.1% across the
range 3.1–33.4 ng/ml and detection limit of 0.5 ng/ml. IL-6 was
measured by ELISA (Quantikine HS, R&D Systems), with an inter-
assay CV of10% across the range 0.15–10 pg/ml and detection limit
of 0.039 pg/ml.
The remaining 5 ml of venous blood was dispensed into a serum
tube and allowed to clot at room temperature for 60 min before being
centrifuged for 10 min at 2,000 g and 4°C. Resultant serum was
dispensed into Eppendorf tubes and stored at 80°C for the subse-
quent analysis of cortisol, insulin, calcium, albumin, and phosphate
(PO4).
Cortisol was measured with an ECLIA on the Roche Modular
E170, with an interassay CV of 6% between 16 and 1,750 nmol/l
and sensitivity of 8 nmol/l. Insulin was measured by ECLIA on a
Cobas e601 (Roche Diagnostics, Burgess Hill, UK), having an inter-
assay CV of6.1% across the range 44–505 pmol/l and sensitivity of
1.8 pmol/l. Calcium, albumin, and PO4 were measured with standard
commercial assays supplied by Roche Diagnostics performed on the
Roche Modular E170. The range of measurement in serum is 0.05–
5.00 mmol/l for calcium, 10–70 g/l for albumin, and 0.10–6.46
mmol/l for PO4.
Statistical Analysis
Data are presented as means  SD, and statistical significance was
accepted at P  0.05. Data were analyzed with SPSS V20. Effects of
exercise were assessed on the PBO trial data with a one-way ANOVA
for normally distributed data and a Friedman’s ANOVA for nonnor-
mally distributed data. Within-exercise variables were analyzed with
a repeated-measures ANOVA. The area under the curve (AUC) with
respect to BASE was calculated for all biochemistry markers from the
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percent change data (27) for the immediate (BASE, EE, R1, and R2)
and short-term (BASE, FU1, FU2, and FU3) responses to exercise.
The two conditions were then compared with a paired-samples t-test
for normally distributed data or a Wilcoxon’s test for nonnormally
distributed data.
RESULTS
BASE Biochemistry
Table 1 shows the mean  SD concentrations for all vari-
ables. There were no differences between trials for any of the
measures taken at BASE (P values from 0.143 to 0.990, data
not shown).
Exercise Variables
There were no significant differences between PBO and
CHO for RPE (P  0.473) or HR (P  0.869), but, as
expected, both increased over the duration of the exercise bout
(P  0.001). There was also no interaction between condition
and time for either RPE (P 0.847) or HR (P 0.170). Blood
glucose concentrations (Fig. 1) remained relatively unchanged
during PBO feeding (BASE: 4.7  0.3 mmol/l, EE: 4.8  0.8
mmol/l, R1: 4.4 0.4 mmol/l, R2: 4.3 0.3 mmol/l) but were
significantly elevated with CHO feeding (P  0.002) at EE
(6.3  0.6 mmol/l) compared with BASE (4.9  0.2 mmol/l).
Blood glucose concentrations were significantly (P  0.001)
higher in the CHO trial than in the PBO trial at EE. Blood
lactate concentrations (Fig. 1) increased significantly from
BASE to EE (P  0.002) before returning back toward BASE
during recovery.
Markers of Bone Metabolism
-CTX increased by between 6% and 14% from BASE to
the follow-up days in the PBO trial (BASE: 0.54  0.14
ng/ml, FU1: 0.56  0.14 ng/ml, FU2: 0.58  0.19 ng/ml,
FU3: 0.61  0.16 ng/ml; Table 1). AUC analysis showed
that the -CTX response to exercise was significantly lower
in the immediate postexercise period with CHO than with
PBO (P  0.028; Fig. 2A), although there was no difference
Table 1. Concentrations of bone turnover markers, modulators of bone metabolism, and markers of calcium metabolism
BASE EE R1 R2 FU1 FU2 FU3
Markers of bone formation and resorption
-CTX, ng/ml
CHO 0.60  0.23 0.43 0.18 0.41 0.20 0.39  0.19 0.58  0.20 0.60  0.17 0.62  0.21
PBO 0.54  0.14 0.45 0.17 0.45 0.19 0.42  0.16 0.56  0.14 0.58  0.19 0.61  0.16
P1NP, ng/ml
CHO 65.1  28.7 73.8 28.3 63.0 24.2 65.7  27.3 65.1  26.0 68.4  29.3 69.7  29.2
PBO 63.1  30.5 77.8 34.9 68.3 29.2 67.7  25.8 67.9  33.2 66.2  31.7 68.4  28.0
OC, ng/ml
CHO 26.6  10.8 29.7 11.5 26.0 9.7 24.0  9.7 25.1  9.1 26.0  8.7 25.5  9.3
PBO 25.1  7.3 29.4 6.6 25.9 8.4 24.3  7.2 22.5  6.9 25.3  9.2 25.6  8.6
Markers of calcium metabolism
PTH, pmol/l
CHO 3.66  0.68 7.13 1.99 3.25 1.41 3.25  0.80 3.84  0.89 3.78  1.21 3.65  0.55
PBO 3.66  1.18 6.55 1.97 3.55 1.23 3.25  1.15 3.85  1.31 3.68  1.37 4.26  2.07
PO4, mmol/l
CHO 1.17  0.22 1.35 0.19 1.01 0.20 1.04  0.11 1.24  0.21 1.13  0.15 1.14  0.13
PBO 1.14  0.11 1.36 0.08 1.13 0.20 1.04  0.14 1.13  0.15 1.02  0.13 1.15  0.15
ACa, mmol/l
CHO 2.20  0.11 2.24 0.06 2.26 0.21 2.18  0.15 2.21  0.09 2.12  0.12 2.15  0.06
PBO 2.15  0.10 2.20 0.11 2.12 0.14 2.15  0.14 2.13  0.15 2.13  0.14 2.14  0.10
Modulators of bone metabolism
Insulin, pmol/l
CHO 68.2  70.7 126.2 99.0 46.0 61.1 23.9  18.5 66.0  55.5 96.6  163.3 81.4  144.2
PBO 54.6  33.1 63.5 23.5 20.0 15.4 22.0  13.5 56.2  66.0 111.7  217.0 64.9 68.0
Cortisol, nmol/l
CHO 449.1  113.5 478.9 196.6 423.3 188.9 354.2 132.9 494.4  119.1 454.8  121.9 438.3 133.0
PBO 485.7  116.5 503.2 80.5 500.1 167.2 470.4 139.6 469.6  155.8 484.3  136.8 468.8 144.1
IL-6, pg/ml
CHO 1.30  0.61 12.17 11.42 10.51 7.96 7.54  4.04 2.2  1.74 1.58  1.12 1.76  1.33
PBO 1.09  0.57 15.36 9.36 11.14 6.16 9.40  3.04 1.56  0.70 1.27  0.47 1.10  0.57
Leptin, ng/l
CHO 3.91  1.40 3.43 1.41 2.95 1.22 2.90  1.24 3.90  1.46 3.87  1.20 4.09  1.15
PBO 4.86  2.74 4.08 2.59 3.63 2.77 3.42  2.70 4.12  2.82 4.30  2.57 3.79  0.61
OPG, pmol/l
CHO 2.46  1.28 3.16 1.55 2.99 0.85 3.30  1.30 2.22  0.87 2.22  0.92 3.29  1.62
PBO 2.55  1.20 2.63 1.05 2.48 1.38 2.84  1.37 2.17  1.06 2.95  1.02 2.73  1.02
GLP-2, ng/ml
CHO 8.28  5.28 10.18 6.52 8.47 4.91 7.69  4.61 9.22  6.51 9.19  5.30 9.08  5.35
PBO 9.13  6.44 9.29 7.08 10.06 7.52 9.09  6.51 9.12  6.05 8.29  4.59 9.44  5.83
Data are mean  SD concentrations of bone turnover markers, modulators of bone metabolism, and markers of calcium metabolism at baseline (BASE),
immediately after exercise (EE), during 2 h of recovery after exercise (R1, R2), and during 3 follow-up days (FU1–FU3) in the carbohydrate (CHO) and placebo
(PBO) trials. -CTX, COOH-terminal telopeptide region of collagen type 1; P1NP, NH2-terminal propeptides of procollagen type 1; OC, osteocalcin; PTH,
parathyroid hormone; ACa, albumin-adjusted calcium; IL-6, interleukin-6; OPG, osteoprotogerin; GLP-2, glucagon-like peptide-2.
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in the short-term response over the follow-up days (P 
0.856; Fig. 2B).
On the follow-up days, P1NP was 5–14% (FU1: 67.9 
33.2 ng/ml, FU2: 66.2  31.7 ng/ml, FU3: 68.4  28.0
ng/ml) higher than at BASE (63.1  30.5 ng/ml) in the PBO
trial (Table 1). AUC analysis showed significantly lower
P1NP concentrations in the CHO trial compared with the
PBO trial in the hours following exercise (P  0.021; Fig.
2A), but there were no differences between trials over the
follow-up days (P  0.721; Fig. 2B).
OC concentrations were not affected by exercise in the PBO
trial (Table 1) or by CHO ingestion during exercise either in
the immediate (P  0.343; Fig. 2A) or short-term (P  0.786;
Fig. 2B) recovery periods.
Modulators of Calcium Metabolism
PTH increased (P 0.001) by 87% at EE (6.6 2.0 pmol/l)
compared with BASE (3.7  1.2 pmol/l) in the PBO trial.
Thereafter, concentrations returned toward BASE levels and
were slightly lower than BASE at R1 (3.6  1.2 pmol/l)
and R2 (3.3  1.3 pmol/l). PO4 was increased by 21% at EE
(1.4  0.1 mmol/l) because of the exercise bout (P  0.001)
and then returned to BASE values (1.1  0.1 mmol/l) by R1
(1.1 0.2 mmol/l). No exercise effect was shown for albumin-
adjusted calcium (ACa) in the PBO trial (P  0.871). There
were no immediate or short-term effects of CHO feeding on
calcium metabolism markers (Table 2).
Other Modulators of Bone Metabolism
Significant effects of exercise (PBO trial) were shown for
insulin (P  0.001), IL-6 (P  0.001), and leptin (P  0.01),
but there were no significant effects of exercise on cortisol,
OPG, or GLP-2. CHO feeding significantly attenuated the
elevation in IL-6 concentrations (223%) seen immediately after
exercise in the PBO trial (Table 2; P  0.036), although these
differences did not persist over the follow-up days (P 0.327).
There were no other immediate or short-term effects of CHO
feeding on any of the remaining modulators of bone metabo-
lism measured (Table 2).
DISCUSSION
Our main findings were that 1) CHO feeding during
exercise attenuated the -CTX and P1NP responses in the
hours but not days following exercise and 2) IL-6 responded
in a similar manner to bone turnover after CHO feeding
during exercise.
The reduction in bone resorption with CHO feeding during
strenuous exercise suggests a potential strategy for athletes and
those performing arduous occupational training (e.g., the mil-
itary recruit) to minimize increased bone resorption resulting
from such exercise (23). From the results of the present
investigation, it should be noted, however, that the magni-
tude of the effect of CHO feeding on -CTX concentrations
was relatively small, which in itself might not be that
clinically significant. If these effects were repeatable over
subsequent strenuous exercise bouts (as would be the case
during athletic or military training programs), however, then
there could be a physiological or clinical benefit. Future
studies should determine the effect of repeated feeding
during exercise across a training program on bone turnover.
It should also be noted that CHO feeding attenuated the
exercise-induced increase in P1NP, indicating that the dy-
namic balance between bone resorption and formation was
maintained. The bone marker responses to CHO ingestion
during exercise in the present study are similar to the
responses observed by others at rest (3), where a reduction
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in -CTX (18%) and P1NP (4%) in response to breakfast
feeding, compared with fasting, was shown. While this is
consistent with the present findings incorporating an exer-
cise intervention, it does not concur with our previous study
(22), which showed that resting concentrations of -CTX,
but not P1NP or OC, were reduced after a preexercise mixed
meal compared with fasting.
One possible explanation for the immediate effects of CHO
feeding on the bone resorption response to exercise is the
concomitant reduction in the IL-6 response, with a strong
correlation (r  0.74, P  0.05) existing between the imme-
diate responses of IL-6 and -CTX in the CHO trial. The
ingestion of CHO before and during endurance exercise atten-
uates the rise in circulating IL-6 associated with exercise (15).
Starkie et al. (24) showed that a total ingestion of 64  3 g of
CHO before and during 60 min of running and cycling atten-
uated the rise in plasma IL-6 associated with both modes of
exercise. Increases in circulating cytokines (16, 17) have been
shown in response to heavy or unaccustomed exercise and
might have a regulatory function in bone metabolism (13),
potentially providing a mechanism that underpins the observed
short-term effect of CHO ingestion during exercise on bone
metabolism. Evidence from in vitro and animal models sug-
gests that IL-6 is an activator of osteoclastogenesis and bone
resorption (12). It can stimulate osteoclast differentiation but
can also, in the presence of soluble IL-6 receptors (sIL-6Rs),
stimulate osteoclast activity (12). Palmqvist et al. (18) have
shown that IL-6, when combined with its soluble receptor,
stimulates bone resorption, as well as mRNA and protein
expression of receptor activator of nuclear factor 	B ligand
(RANKL) and OPG in murine calvarial bone. sIL-6R can bind
its ligand and induce cellular responses through association
with the glycoprotein 130 receptor subunit (gp130), thus
acting as an IL-6 agonist. IL-6 stimulates gp130 on stromal
or osteoblastic cells, subsequently resulting in downstream
signal transducer and activator transcription 3-mediated
expression of RANKL and stimulation of osteoclast forma-
tion. In addition, others (20) have suggested the presence of
a T-cell cytokine that can stimulate IL-6 in human osteo-
blastic cells. While this indicates a potential mechanism for
the present findings, it should be noted that there was no
effect of CHO feeding on circulating OPG concentrations
and we cannot confirm the circulating sIL-6R or RANKL
concentrations in the present study. Previous studies have
suggested an effect of exercise on sIL-6R concentrations
(for review see Ref. 19), but there is no study, to our
knowledge, that has reported the effects of CHO feeding.
The measurement of circulating RANKL concentrations was
not possible in the present study because of the lack of a
suitable assay. In addition, when measuring the circulating
concentrations of molecules it is not possible to be certain of
the biological actions occurring in particular tissues.
There was a significantly attenuated P1NP response in the
hours after exercise in the CHO trial compared with the PBO
trial, suggesting that CHO feeding during prolonged exercise
affects bone formation in addition to bone resorption. There
was no concomitant effect on circulating OC concentrations,
which is inconsistent with the P1NP and IL-6 responses to
CHO ingestion during exercise in the present study, since some
have suggested that it is a marker of coupled bone turnover (9),
is capable of suppressing IL-6 release (8), and has importance
in the relationship between bone remodeling and energy me-
tabolism (6).
The response of P1NP in concert with the effect shown on
-CTX would suggest that CHO feeding during exercise re-
duced overall bone turnover in the hours following exercise but
the balance between resorption and formation was maintained.
While a reduction in IL-6 release during exercise with CHO
feeding is a plausible mechanism to explain the observed
reduction in -CTX concentrations, the reason for the attenu-
ated postexercise P1NP concentrations with CHO feeding
during exercise is currently unknown but is likely to involve
cellular cross talk between the osteoclasts and osteoblasts,
given their very close association.
Potential mechanisms for the suppression of bone turn-
over by CHO feeding during exercise relate to effects on
PTH or on the incretin and enteric hormones. Bone turnover
was decreased along with PTH in a previous study employ-
ing the hypoglycemic clamping technique (4), suggesting
that short-term alterations to bone turnover are due to direct
effects of hypoglycemia (glucose concentrations were
clamped at 2.5 mmol/l for 105 min) on bone cells or are
mediated by changes in regulatory hormone concentrations
triggered by hypoglycemia (4). The present study did not
show any immediate effect of CHO provision during exer-
cise on the circulating concentrations of PTH, ACa, or PO4,
making it unlikely that the effects of CHO supplementation
during exercise on bone turnover were mediated by altera-
Table 2. Immediate and short-term data for changes in modulators of bone and calcium metabolism during exercise
n
Immediate Responses, %/4 h Short-Term Responses, %/72 h
PBO CHO P value PBO CHO P value
Markers of calcium metabolism
PTH, pmol/l 10 9  10 8  13 0.801 1 16 3  19 0.812
PO4, mmol/l 8 1  5 2  6 0.246 6  5 2  9 0.040
ACa, mmol/l 8 0  3 1  3 0.624 0 2 2  4 0.239
Modulators of bone metabolism
Insulin, pmol/l 8 15  17 1  26 0.112 22 59 3  23 0.208
Cortisol, nmol/l 8 3  19 0  25 0.779 2  17 5  13 0.595
IL-6, pg/ml 8 625  337 398  384 0.036 70  230 58  143 0.327
Leptin, ng/ml 7 14  6 12  5 0.201 0  1 2  11 0.622
OPG, pmol/l 8 9  26 25  35 0.109 34 80 26  66 0.674
GLP-2, ng/ml 10 2  10 6  9 0.422 2  17 4  21 0.508
Data are mean  SD changes in concentration of modulators of bone and calcium metabolism with or without CHO supplementation during exercise.
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tions in calcium metabolism. CHO did not significantly alter
the immediate or short-term responses of leptin, insulin,
cortisol, or GLP-2 to exercise, indicating that alterations in
these hormones were also unlikely to be responsible for the
effect of CHO supplementation on bone turnover. Despite
the fact that the present study involved 120 min of running
at 70% V˙ O2 max, blood glucose concentrations remained
relatively stable, even when participants were not fed CHO
in the PBO trial, with blood glucose concentrations not
reaching hypoglycemic levels.
Given that the data from the PBO trial show a 5–15%
increase in -CTX during the follow-up days compared with
BASE, and others (23) also report greater and more prolonged
increases in -CTX following exhaustive exercise, it is clear
that CHO feeding during exercise alone might not be sufficient
to result in a more prolonged or greater suppression of the
increase in bone resorption. This might be because the amount
of CHO provided (102.1  10.6 g) during exercise was not
sufficient to prolong the effect observed during the immediate
recovery period, possibly because the CHO was used by the
muscle to support glycogen resynthesis. Another possibility is
that participants resumed their habitual diet once leaving the
laboratory on day 4, meaning that any extra CHO provided
during exercise in the CHO trial would become less meaning-
ful as a proportion of the total daily energy intake. As such, the
clinical implications of the present study findings remain un-
clear; future work could explore higher CHO intakes during
exercise or the maintenance of high CHO intakes in the days
following exercise for skeletal benefits. The amount of CHO
provided during exercise in the present study (50 g/h) is
consistent with the amount and rate typically recommended for
endurance exercise benefits (10), although in current practice
athletes typically consume 60–70 g/h (11) and athletes per-
forming prolonged exercise (e.g., triathletes) are advised to
increase their CHO intake (from multiple CHO sources) to
80–90 g/h (11).
In conclusion, CHO supplementation during prolonged run-
ning reduced bone turnover in the hours following exercise. A
possible mediator of the immediate bone resorption response to
exercise when CHO was fed during exercise was IL-6. The
mechanism underlying the reduced P1NP response remains
unknown. No changes in markers of calcium metabolism or
incretin and enteric hormone concentrations were observed
with CHO feeding, suggesting that they are unlikely mediators
of the effect of CHO on bone turnover.
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